<DOC>
	<DOC>NCT00877253</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.</brief_summary>
	<brief_title>Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer</brief_title>
	<detailed_description>This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of the combination therapy with Genexol®-PM and Carboplatin and to evaluate the efficacy and safety of Genexol®-PM when administered with Carboplatin in subjects with advanced ovarian cancer after debulking surgery.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Women ≥ 18 years old. Signed informed consent before inclusion. Subjects who have histologically or cytologically confirmed advanced epithelial ovarian cancer.(FIGO IIIBIV) Subjects who have measurable disease by RECIST after debulking surgery. ECOG performance status of 0, 1, or 2. Estimated life expectancy of more than 6 months Subjects who have the clinically acceptable function of blood, kidney and liver at screening visit Hb ≥ 10g/dl ANC ≥ 1.5×10^9/L Platelet Count ≥ 100×10^9/L Serum total bilirubin ≤ 1.5×ULN Serum AST and ALT ≤ 2.5×ULN Serum ALP ≤ 2.5×ULN Serum creatinine ≤ 1.5×ULN Subjects who have received chemotherapy for ovarian cancer other than debulking surgery. Subjects who have a history of radiotherapy to pelvis or abdominal cavity Subjects who receive immunotherapy or hormonal therapy for ovarian cancer Subjects who have other malignancies within the past 5 years Subjects who have had a major surgery other than debulking surgery within 2 weeks prior to the screening/baseline visit Subjects who have a history of metastasis or currently have a metastasis to the central nervous system(CNS) Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 1 based on NCI CTCAE V3.0 Subjects who have serious medical condition Uncontrolled or severe cardiovascular disease(Ischemic heart disease, myocardial infarction within the last 6 months, congestive heart failure) Uncontrollable infection Previous allergic reactions in connection with paclitaxel and carboplatin Subjects who participate another clinical trial within the last 4 weeks before inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>